Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 3/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.31 |
| ▸ | SIRT3 | Q9NTG7 | 5/20 | 0.31 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1630838 | 0.79 | CYP11B1 (0.40) | CYP11B1CYP11B2 | |
| SCHEMBL31124717 | 0.79 | TRPA1 (0.35) | — | |
| SCHEMBL1853659 | 0.76 | AKR1B1 (0.34) | MAOB | |
| SCHEMBL31160243 | 0.76 | MEN1 (0.43) | SIRT2SIRT1SIRT3 | |
| SCHEMBL31160298 | 0.74 | SIRT2 (0.37) | MAPK1NOS1NOS2MAOBSIRT2 | |
| SCHEMBL31160268 | 0.74 | SIRT2 (0.46) | SIRT2SIRT1SIRT3GPR132 | |
| SCHEMBL5106543 | 0.73 | CYP4F2 (0.42) | MAOB | |
| SCHEMBL3932476 | 0.72 | TACR1 (0.43) | MAPK1 | |
| SCHEMBL501339 | 0.70 | TACR1 (0.32) | — | |
| SCHEMBL5782201 | 0.70 | ABCB1 (0.43) | MAPK1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025001407-A1 | POLYARYL-CONTAINING MACROCYCLIC COMPOUNDS AND USES THEREOF | 浙江养生堂天然药物研究所有限公司 | 2025-01-02 | — | — | WO | disclosed |